A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases.

IF 4 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Marko Radojković, Aleksandra Chikunova, Saar F Koene, Monika Timmer, Sivanandam V Natarajan, Aimee L Boyle, Marcellus Ubbink
{"title":"A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases.","authors":"Marko Radojković, Aleksandra Chikunova, Saar F Koene, Monika Timmer, Sivanandam V Natarajan, Aimee L Boyle, Marcellus Ubbink","doi":"10.1016/j.jbc.2025.110347","DOIUrl":null,"url":null,"abstract":"<p><p>β-Lactamase enzymes exhibit extraordinary adaptive potential, thus rendering many β-lactam drugs ineffective. The residue at Ambler position 105, also known as the gatekeeper residue, plays an important role in substrate recognition, but its implication in inhibition mechanisms is understudied and obscure. To inspect the relationship between inhibitor-resistant phenotypes and residues at this position, we performed site-saturation mutagenesis and extensive fitness profiling of five distinct class A β-lactamases using deep sequencing. We found that inhibitor resistance is readily detectable, with variants harboring Gly or Arg being the least susceptible to inhibitors. Mutation of Ile105 to Arg in the β-lactamase BlaC simultaneously enhances activity for carbenicillin and the ability to evade clavulanic acid inhibition. The Y105G substitution in two clinically important enzymes, CTX-M-14 and TEM-1, confers greatly reduced in vitro sensitivity to avibactam, which we attribute to elevated conformational flexibility of the inhibitor within the active site. The findings presented in this study underpin the gatekeeper residue as a possible mutational hotspot and might aid the design of novel β-lactamase inhibitors.</p>","PeriodicalId":15140,"journal":{"name":"Journal of Biological Chemistry","volume":" ","pages":"110347"},"PeriodicalIF":4.0000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biological Chemistry","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.jbc.2025.110347","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

β-Lactamase enzymes exhibit extraordinary adaptive potential, thus rendering many β-lactam drugs ineffective. The residue at Ambler position 105, also known as the gatekeeper residue, plays an important role in substrate recognition, but its implication in inhibition mechanisms is understudied and obscure. To inspect the relationship between inhibitor-resistant phenotypes and residues at this position, we performed site-saturation mutagenesis and extensive fitness profiling of five distinct class A β-lactamases using deep sequencing. We found that inhibitor resistance is readily detectable, with variants harboring Gly or Arg being the least susceptible to inhibitors. Mutation of Ile105 to Arg in the β-lactamase BlaC simultaneously enhances activity for carbenicillin and the ability to evade clavulanic acid inhibition. The Y105G substitution in two clinically important enzymes, CTX-M-14 and TEM-1, confers greatly reduced in vitro sensitivity to avibactam, which we attribute to elevated conformational flexibility of the inhibitor within the active site. The findings presented in this study underpin the gatekeeper residue as a possible mutational hotspot and might aid the design of novel β-lactamase inhibitors.

在A类β-内酰胺酶中,位于105位的甘氨酸导致克拉维酸和阿维巴坦耐药。
β-内酰胺酶具有非凡的适应潜力,因此使许多β-内酰胺类药物无效。Ambler位置105的残基,也被称为看门人残基,在底物识别中起重要作用,但其在抑制机制中的意义尚不清楚。为了检查抗抑制剂表型与该位置残基之间的关系,我们使用深度测序对五种不同的A类β-内酰胺酶进行了位点饱和诱变和广泛的适应度分析。我们发现抑制剂耐药性很容易检测到,含有Gly或Arg的变异对抑制剂最不敏感。β-内酰胺酶BlaC中的Ile105突变为精氨酸,同时增强了对卡比西林的活性和逃避克拉维酸抑制的能力。Y105G取代两种临床重要酶CTX-M-14和TEM-1,大大降低了体外对阿维巴坦的敏感性,我们将其归因于活性位点内抑制剂构象灵活性的提高。本研究的发现支持守门人残基作为一个可能的突变热点,并可能有助于设计新的β-内酰胺酶抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biological Chemistry
Journal of Biological Chemistry Biochemistry, Genetics and Molecular Biology-Biochemistry
自引率
4.20%
发文量
1233
期刊介绍: The Journal of Biological Chemistry welcomes high-quality science that seeks to elucidate the molecular and cellular basis of biological processes. Papers published in JBC can therefore fall under the umbrellas of not only biological chemistry, chemical biology, or biochemistry, but also allied disciplines such as biophysics, systems biology, RNA biology, immunology, microbiology, neurobiology, epigenetics, computational biology, ’omics, and many more. The outcome of our focus on papers that contribute novel and important mechanistic insights, rather than on a particular topic area, is that JBC is truly a melting pot for scientists across disciplines. In addition, JBC welcomes papers that describe methods that will help scientists push their biochemical inquiries forward and resources that will be of use to the research community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信